GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab, Bristol Myers Squibb's anti-PD-1 therapy, as ...
Scientists at the University of Utah's Huntsman Cancer Institute analyzed the results of 14 studies by scientists all over the world associated with the International Headand NeckCancer ...